Nvidia’s venture arm invests $10.4 million in Generate Biomedicines, a clinical-stage biotech using AI to design novel therapeutics.
Nvidia holds a $10.4 million stake in Generate Biomedicines (GENB), a clinical-stage biotech leveraging artificial intelligence to engineer protein therapeutics. The investment, made through NVentures, underscores confidence in GENB’s AI platform, which designs novel drugs from scratch rather than modifying existing compounds.
Generate Biomedicines went public in February and has seen its shares rise over 12% this year. Its lead candidate, GB-0895, is in phase 3 trials for severe asthma and early-stage trials for COPD, validating its computational models in human studies.
The company’s proprietary machine-learning models, including the Chroma platform, target disease pathways considered undruggable by traditional methods. Nvidia’s backing highlights growing interest in AI-driven drug discovery among major tech investors.